The device is currently available in the US, Europe, Canada, and Australia.

It will facilitate access to challenging anatomies and branch vessels such as common iliac arteries during endovascular repair procedures.

The 12 Fr x 45cm sheath configuration of DrySeal has been formulated for use with Gore Excluder iliac branch endoprosthesis (IBE), the device indicated in the US for endovascular repair (EVAR) of common iliac artery aneurysms or aortoiliac aneurysms.

The sheath’s exclusive DrySeal valve will enable to minimize blood loss and introduce multiple devices with proven hemostasis control.

With kink resistance and hydrophilic coating, the DrySeal device is available in working lengths of 33cm, 45cm, and 65cm.

Gore aortic business leader Ryan Takeuchi said: “By linking our tested GORE DrySeal Flex Introducer Sheath with our endovascular portfolio, we continue to make great strides in advancing patient care.

“We remain committed to making these innovative devices available to treat more patients globally.”

Earlier this month, Gore received pproval from the US Food and Drug Administration (FDA) for its Tigris dual-component vascular stent to treat peripheral artery disease (PAD).

Tigris device, which is a third generation and self-expanding stent, has been designed to improve anatomical conformability with the natural movement of the knee when treating PAD.

Image: Gore DrySeal Flex introducer sheath. Photo: courtesy of Business Wire.